Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial - Fuchs, C S; Tomasek, J; Yong, C J (The Lancet, 2014)
et al.